5630-53-5
5630-53-5
Chemical Structure
Tibolone
- CAS No.: 5630-53-5
- Formula:C21H28O2
- Molecular Weight:312.45
IUPAC Name: (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: WZDGZWOAQTVYBX-XOINTXKNSA-N
SMILES: C[C@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](O)(CC3)C#C)(CC[C@]2([H])C4=C(CC(CC4)=O)C1)C
Biological Activity: Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tibolone | 99.9% | Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tibolone (Standard) | ≥98% | Tibolone (Standard) is the analytical standard of Tibolone. This product is intended for research and analytical applications. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tibolone-d5 | Tibolone-d5 is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3β hydroxy Tibolone-d5 | 3β hydroxy Tibolone-d5 is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dragos Apostu, et al. Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model. Clin Oral Implants Res. 2020 Jul;31(7):655-668. [Content Brief]
- [2]. Marcos García-Juárez, et al. Tibolone induces lordosis behavior, but not concurrent or sequential inhibition, in Sprague Dawley rats. Neurosci Lett. 2021 Apr 24;755:135916. [Content Brief]
